Clinical Trials Logo

Filter by:
NCT ID: NCT06412224 Recruiting - Clinical trials for PDR - Proliferative Diabetic Retinopathy

The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

Start date: December 20, 2023
Phase: Early Phase 1
Study type: Interventional

This study aims to slow down disease progression, reduce postoperative complications and decrease retreatment frequency in subjects with proliferative diabetic retinopathy (PDR) by administering a single subretinal injection of RRG001 gene therapy after vitrectomy.

NCT ID: NCT06411743 Completed - Hepatic Ascites Clinical Trials

Phase II/III of Recombinant Human Albumin Injection

Start date: September 7, 2021
Phase: Phase 2
Study type: Interventional

This study was a Phase II/III multicenter, blinded, and positiveactive-controlled clinical study with seamless adaptive design to evaluate the dose-response relationship, safety, and immunogenicity of recombinant human albumin(rHA) injection for the treatment of hypoalbuminemia in cirrhotic patients with ascites, and to provide a reference for the design of the Phase III clinical study.

NCT ID: NCT06411717 Recruiting - Myopia Clinical Trials

A Clinical Trial to Evaluate the Efficacy and Safety of Defocusing Lenses in Delaying Myopia Progression

Start date: April 7, 2024
Phase: N/A
Study type: Interventional

The objective of this clinical trial was to evaluate the efficacy and safety of defocusing lenses for delaying myopia progression in children and adolescents. A total of 156 subjects meeting the requirements of the study protocol were included. During the study, subjects were required to wear the test product (defocus lens A or defocus lens B) or the control product (aspheric lens) for 12 months, and regular follow-up was required during the wearing process, including various ophthalmological examinations and subjective feelings about wearing the lens. During the study period, the product status, ocular conditions, adverse events and serious adverse events were continuously observed to evaluate the safety and effectiveness of the test product in clinical use.

NCT ID: NCT06411678 Not yet recruiting - Breast Cancer Clinical Trials

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

Start date: May 10, 2024
Phase: Early Phase 1
Study type: Interventional

We plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study on breast cancer patients to observe the binding of the tracer to lesions and evaluate CD73 expression. Alongside this, we will correlate these imaging results with relevant clinical indicators to assess the effectiveness of 68Ga-DOTA-dPNE in diagnosing and guiding treatment in breast cancer patients. This study aims to predict responses to targeted therapies.

NCT ID: NCT06411470 Recruiting - Pancreatic Cancer Clinical Trials

Gastrointestinal Microflora and Serum Metabolomics in Patients With Pancreatic Cancer and Chronic Pancreatitis

Start date: April 20, 2024
Phase:
Study type: Observational

The investigators plan to collect throat swabs, saliva, feces and serum samples from pancreatic cancer patients, chronic pancreatitis patients and healthy people and clarify the characteristics of oral flora and serum metabolome of pancreatic cancer patients.

NCT ID: NCT06411457 Recruiting - Breast Cancer Clinical Trials

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Start date: May 16, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer

NCT ID: NCT06411275 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

Start date: March 31, 2022
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes inadequately controlled with diet and exercise alone.

NCT ID: NCT06411236 Not yet recruiting - Dysphagia Clinical Trials

Functional Response Characteristics of Brain Under Swallowing Task Paradigm

Start date: May 10, 2024
Phase:
Study type: Observational

Functional near-infrared spectroscopy was used to investigate the cortical activation patterns and lateralization during swallowing tasks in 15 healthy middle-aged and elderly people and 15 healthy young people. It provides a theoretical basis for the study of swallowing function and a new idea for the treatment of patients with swallowing disorders.

NCT ID: NCT06410859 Enrolling by invitation - Clinical trials for Trigeminal Neuralgia

Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia

Start date: April 25, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration scheme of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of TN.

NCT ID: NCT06410833 Recruiting - Pediatric ALL Clinical Trials

Belimumab After Rituximab in Resistant Primary Juvenile SS

BRRPJS
Start date: March 9, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome. Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients Researchers will compare the disease activity before and after the treatment of sequential use of rituximab and belimumab to see if the therapy works to treat SS. Participants will: Recieve Rituximab each week for 2-4 times until B%<0.5% or B#<20×10^6/L Recieve Belimumab 4 weeks after the last use of Rituximab, and then every 4 weeks until week 28